Intracellular Th (ITCI)

NASDAQ
Currency in USD
131.87
0.00(0.00%)
Closed·
Trading near 52-week High
Day's Range
131.63131.98
52 wk Range
64.09131.98
Key Statistics
Edit
Prev. Close
131.87
Open
131.9
Day's Range
131.63-131.98
52 wk Range
64.09-131.98
Volume
-
Average Volume (3m)
2.84M
1-Year Change
83.15%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
Show more

Intracellular Th Company Profile

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company that develops and commercializes therapeutics and small molecule drugs for central nervous system (CNS), neuropsychiatric, and neurological disorders. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It distributes its products through third-party wholesale drug distributors. The company was founded in 2002 and is based in Bedminster, New Jersey. As of April 2, 2025, Intra-Cellular Therapies, Inc. operates as a subsidiary of Johnson & Johnson Innovative Medicine.

Employees
860

Intracellular Th SWOT Analysis


CAPLYTA's Triumph
Explore CAPLYTA's market success, driving Intra-Cellular Therapies' growth with Q3 revenue of $175.2 million and potential to reach $5 billion in mood disorders
Patent Predicament
Delve into the complex patent landscape, balancing extended protection until 2034 against potential challenges from generic competitors
Pipeline Promise
Discover Intra-Cellular's strategic pipeline developments, including long-acting injectables and ITI-1284, diversifying beyond CAPLYTA
Market Momentum
Analyst targets range from $96 to $135, reflecting optimism in CAPLYTA's expansion and Intra-Cellular's robust financial performance
Read full SWOT analysis

Intracellular Th Earnings Call Summary for Q1/2024

  • CAPLYTA sales surged 53% YoY to $144.8M in Q1 2024; full-year guidance maintained at $645M-$675M
  • Positive results for Lumateperone in MDD; FDA filing planned for H2 2024
  • Strong cash position of $477.4M after $575M public offering; expanding sales force and product portfolio
  • Ongoing clinical programs for Alzheimer's, Parkinson's, and autism spectrum disorders
  • Growing CAPLYTA prescriber base and improved Medicare Part D access support continued growth outlook
Last Updated: 08-05-2024, 01:34 am
Read Full Transcript

Compare ITCI to Peers and Sector

Metrics to compare
ITCI
Peers
Sector
Relationship
P/E Ratio
0.0x0.0x0.0x
PEG Ratio
0.000.000.00
Price/Book
0.0x0.0x0.0x
Price / LTM Sales
0.0x0.0x0.0x
Upside (Analyst Target)
0.0%0.0%0.0%
Fair Value Upside
Unlock0.0%0.0%Unlock

Earnings

Latest Release
Feb 21, 2025
EPS / Forecast
-0.16 / -0.0731
Revenue / Forecast
199.22M / 194.02M
EPS Revisions
Last 90 days
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.